Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that The Lancet published detailed data from the...

Related Keywords

Australia ,United Kingdom ,Canada ,Northbrook ,Queensland ,United States ,Japan ,Tokyo ,American ,America ,Pranob Bhattacharya ,Naoki Okamura ,Kohei Shitara ,American Cancer Society ,End Results Program ,Department Of Gastrointestinal Oncology ,Astellas Pharma Inc ,American Society Of Clinical Oncology ,Prnewswire Astellas Pharma Inc ,Oncology Development ,National Cancer Center Hospital ,National Cancer Institute ,Clinical Oncology ,Primary Investigator ,Gastrointestinal Oncology ,National Cancer Center Hospital East ,Executive Director ,Interim Head ,Immuno Oncology Development ,March American Society ,Locally Advanced Unresectable Metastatic Gastric ,Gastroesophageal Junction ,South America ,Hazard Ratio ,Primary Focus ,Focus Area Approach ,Astellas Pharma ,End Results ,